
When Can I Order My Tesla Optimus Robot?
I’m excited to say I don’t think we’ll have to wait too long for our own humanoid robots.
Profiting from the leading edge of tech, with high-tech insider and angel investor Jeff Brown.
Sign UpThe only place in the universe to find insights and analysis on the world of tech, the markets, and the perpetual chaos around us, from high-tech executive and angel investor Jeff Brown. Please enter your email to start getting his personal intel on what’s happening behind closed doors.
I’m excited to say I don’t think we’ll have to wait too long for our own humanoid robots.
I couldn’t help but think of Bladerunner, as I’ve immensely enjoyed watching the new Tesla Cybertruck roll off of production lines for the first time over the last few weeks.
The stock market has overestimated the Fed's ability to make aggressive cuts to interest rates this year.
This week, we’re going to do another deep dive on an exciting small cap stock that is a next generation surgical robotics company.
I remain as passionate as ever about providing access to private markets for Brownridge Research subscribers.
Are SPACs still a great alternative to traditional IPOs?
"Manifested AI" refers to AI technology that has manifested itself into forms that we can easily interact with, and it will be one of the biggest trends of 2024.
Channel 1, the AI News Network, will be entirely powered by artificial intelligence.
We’re going to take a fresh look at an incredible small cap semiconductor company — Akoustis (AKTS).
Jeff Brown has more than three decades of experience as a high-tech executive, investor, and investment research analyst.
He's widely known for his candid and untarnished analysis and insights into the world of tech, biotech, economics, and investment research. Millions have read and enjoyed his work at his most recent role as founder and chief investment analyst at Brownstone Research, where he worked and published for 8 years.